| Malignant Fallopian Tube Neoplasm studied in …STUDIED_INderived200 of 744show all (up to 200) |
|---|
| → studied in | NCT02345265Phase 2 · active not recruiting Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05287451NA · recruiting Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06890338Phase 2 · recruiting A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07402915Phase 1 · recruiting Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05867251Phase 1/Phase 2 · recruiting Study of AVZO-021 in Patients With Advanced Solid Tumors · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07843303Phase 2 · not yet recruiting Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase II,Multicenter, Single-Arm Study · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03564340Phase 1/Phase 2 · recruiting Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04590326Phase 1/Phase 2 · recruiting A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07776691Phase 3 · recruiting A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07708753Phase 3 · recruiting A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Platinum-Resistant Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05276973Phase 1 · active not recruiting Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05446298Phase 2 · active not recruiting ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06714617Phase 1 · terminated Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07495124Phase 2 · recruiting IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00515372Phase 1 · active not recruiting Depression Treatment and Screening in Ovarian Cancer Patients · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05080946early Phase 1 · suspended Using Aspirin to Improve Immunological Features of Ovarian Tumors · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05739981Phase 1/Phase 2 · recruiting Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06915025Phase 3 · recruiting Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01012817Phase 1/Phase 2 · active not recruiting Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04575935Phase 3 · recruiting Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05059444recruiting ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05858736Phase 1 · completed Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06787612Phase 2 · recruiting Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07772869NA · recruiting Uterine Lavage to Detect Ovarian Cancer Risk · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07743164Phase 3 · not yet recruiting A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07764744NA · not yet recruiting Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Serous Tubal Intraepithelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07815704Phase 2 · not yet recruiting Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02101775Phase 2 · active not recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07811271Phase 3 · not yet recruiting Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02595892Phase 2 · active not recruiting Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06834672Phase 3 · active not recruiting Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02208375Phase 1 · active not recruiting mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06824467Phase 3 · recruiting A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00086567completed Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07791732Phase 3 · not yet recruiting A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01081262Phase 3 · active not recruiting Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02142803Phase 1 · active not recruiting TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02839707Phase 2/Phase 3 · active not recruiting Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06492070Phase 2 · recruiting Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04034927Phase 2 · active not recruiting Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05281471Phase 3 · recruiting Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07771400not yet recruiting Molecular Ovarian Cancer Assessment in LatiNoAmerican PAtients · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02068794Phase 1/Phase 2 · active not recruiting MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03188432Phase 2 · completed Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03355976Phase 2 · active not recruiting BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04673448Phase 1 · active not recruiting Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03604315Phase 1 · recruiting Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03740165Phase 3 · completed Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07772882Phase 1 · not yet recruiting Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05415709early Phase 1 · active not recruiting Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05463796recruiting InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Serous Tubal Intraepithelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06792552Phase 1 · recruiting A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05231122Phase 2 · recruiting Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02217956Phase 1 · completed Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03943173early Phase 1 · active not recruiting Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02884648Phase 2 · active not recruiting Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04415944Phase 2 · completed Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05114421Phase 2 · active not recruiting Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Fallopian Tube High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06580314Phase 3 · recruiting Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00799110Phase 2 · terminated Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03026062Phase 2 · completed Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Platinum-Resistant Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04739800Phase 2 · active not recruiting Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Mucinous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05554328Phase 2 · active not recruiting Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05579366Phase 1/Phase 2 · recruiting Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02627443Phase 1 · active not recruiting Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04616534Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04657068Phase 1/Phase 2 · recruiting A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07285044Phase 2 · recruiting The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05460000Phase 2 · recruiting A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06856499Phase 1 · recruiting Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07690332not yet recruiting A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α（FRα） · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03586661Phase 1 · completed Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04092270Phase 1 · active not recruiting A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04469764Phase 2 · recruiting Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03113487Phase 2 · active not recruiting P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Platinum-Resistant Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03579316Phase 2 · active not recruiting Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05092373Phase 1 · recruiting Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05465941Phase 2 · active not recruiting PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06906341Phase 2 · recruiting Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01116648Phase 1/Phase 2 · active not recruiting Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05887609Phase 2 · recruiting An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07322094Phase 1/Phase 2 · recruiting CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02650986Phase 1/Phase 2 · active not recruiting Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03587311Phase 2 · active not recruiting Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01883297Phase 1 · active not recruiting "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02520154Phase 2 · completed Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06994195Phase 3 · recruiting A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05429970NA · recruiting A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07674615Phase 1 · not yet recruiting IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04387227Phase 2 · completed Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05377996Phase 1/Phase 2 · recruiting A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07545460Phase 3 · not yet recruiting A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07667192recruiting Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02489006Phase 2 · active not recruiting A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03872947Phase 1 · active not recruiting A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05071937Phase 2 · recruiting ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05538091Phase 2 · recruiting Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Platinum-Resistant Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02834013Phase 2 · active not recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04055649Phase 2 · recruiting ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Platinum-Resistant Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07648745Phase 2 · completed Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02759588Phase 1/Phase 2 · completed Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02726997Phase 1/Phase 2 · active not recruiting Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04027868completed Genomic BRCA and Extensive ovArian Cancer Testing · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00951496Phase 3 · completed Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05445778Phase 3 · active not recruiting Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06024109recruiting Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06730347Phase 2 · recruiting A Study of Lorigerlimab in Participants With Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Platinum-Resistant Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07024784Phase 2 · recruiting A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07617753Phase 1/Phase 2 · recruiting Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01167712Phase 3 · active not recruiting Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06682988Phase 2 · recruiting A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04811703Phase 1 · recruiting Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03430700Phase 2 · completed Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04701645Phase 1 · recruiting Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07591831Phase 2 · not yet recruiting Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07586826Phase 2 · recruiting Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04295577completed Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04314401active not recruiting National Cancer Institute "Cancer Moonshot Biobank" · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05691504Phase 1 · active not recruiting Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05271318Phase 1/Phase 2 · active not recruiting Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Platinum-Resistant Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03393884Phase 1/Phase 2 · active not recruiting Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05969860Phase 2 · recruiting At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06295965recruiting Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05659381Phase 3 · recruiting Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02659241early Phase 1 · active not recruiting Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06274541completed Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06710548NA · recruiting REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04516447Phase 1 · recruiting A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03017131Phase 1 · active not recruiting Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05335993Phase 2 · active not recruiting A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06342986Phase 1 · active not recruiting Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02873962Phase 2 · active not recruiting A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04498117Phase 3 · active not recruiting Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06290193Phase 2 · recruiting Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06969833NA · recruiting Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02122185Phase 2 · completed Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04095364Phase 3 · active not recruiting Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07489300Phase 2 · not yet recruiting Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04919629Phase 2 · recruiting APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03922776NA · terminated Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04539327completed Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05198804Phase 1/Phase 2 · completed A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07480954Phase 1/Phase 2 · recruiting Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06483048Phase 1 · recruiting MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Platinum-Resistant Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07472140Phase 2/Phase 3 · recruiting PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05763199Phase 2 · active not recruiting Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03968406Phase 1 · recruiting Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05494580Phase 1/Phase 2 · completed Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07460180Phase 1/Phase 2 · recruiting The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06184867NA · completed Choices About Genetic Testing And Learning Your Risk With Smart Technology · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01970722Phase 1 · active not recruiting Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05574673recruiting Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07432594Phase 2 · not yet recruiting Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05527184Phase 1 · active not recruiting First in Human Study of IMGN151 in Recurrent Gynaecological Cancers · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03771651early Phase 1 · active not recruiting Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04781088Phase 2 · active not recruiting Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Platinum-Resistant Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03296826recruiting Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2 · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06469281Phase 1 · recruiting A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06483997active not recruiting Diet, Hepcidin, and Chemotherapy RDI · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07362147NA · not yet recruiting Exploring the Effects of Hand and Foot Exercise Intervention in Older Adults With Gynecological Cancer Receiving Chemotherapy Improvement of Peripheral Neuropathy and Quality of Life · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05041257Phase 2 · completed Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02948426Phase 1 · terminated Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04204811NA · active not recruiting Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06173037Phase 2 · completed RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06545617Phase 1/Phase 2 · withdrawn A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06855706NA · recruiting An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03189108terminated Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00565851Phase 3 · active not recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05220033NA · active not recruiting Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05483933Phase 1 · completed Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06690775Phase 2 · recruiting CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02364713Phase 2 · terminated MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07269574not yet recruiting Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06007586Phase 3 · completed Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06870539completed Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment · condition mapped ONTOLOGY_EXACT · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05236686NA · recruiting Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03839524Phase 1 · completed A Trial Evaluating TG4050 in Ovarian Carcinoma. · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02111941early Phase 1 · completed Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05456685Phase 2 · active not recruiting Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06617923Phase 2 · recruiting Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03325634Phase 1 · completed Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06084416Phase 1 · active not recruiting A Study of Sovilnesib in Subjects With Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03776812Phase 2 · completed Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06639074Phase 2 · recruiting Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05870748Phase 2/Phase 3 · terminated REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05200364Phase 1 · terminated A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03029403Phase 2 · active not recruiting Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06451263NA · active not recruiting Nudge to Gynecologic Oncology · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05009082Phase 3 · recruiting Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07154966completed Taste Alteration, Sarcopenia, and Malnutrition in Gynecologic Cancer Patients Receiving Carboplatin-Paclitaxel Chemotherapy · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02498600Phase 2 · completed Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped CURATED_BROADER · 744 trials mapped (185 active) | — | — | Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05092360Phase 3 · terminated Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04209855Phase 3 · completed A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03748186Phase 1 · completed Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05708924Phase 1 · terminated MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer · condition mapped ALIAS · 744 trials mapped (185 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |